Last reviewed · How we verify
ABT-348 and azacitidine
AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.
AZA is a hypomethylating agent that targets DNA methyltransferase enzymes. Used for Acute myeloid leukemia, Myelodysplastic syndromes.
At a glance
| Generic name | ABT-348 and azacitidine |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Hypomethylating agent |
| Target | DNA methyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZA works by inhibiting DNA methyltransferase enzymes, leading to the reactivation of silenced genes and the induction of apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia
- Myelodysplastic syndromes
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-348 and azacitidine CI brief — competitive landscape report
- ABT-348 and azacitidine updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI